Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
Cocco E, Javier Carmona F, Razavi P, Won HH, Cai Y, Rossi V, Chan C, Cownie J, Soong J, Toska E, Shifman SG, Sarotto I, Savas P, Wick MJ, Papadopoulos KP, Moriarty A, Cutler RE Jr, Avogadri-Connors F, Lalani AS, Bryce RP, Chandarlapaty S, Hyman DM, Solit DB, Boni V, Loi S, Baselga J, Berger MF, Montemurro F, Scaltriti M.
Cocco E, et al. Among authors: toska e.
Sci Signal. 2018 Oct 9;11(551):eaat9773. doi: 10.1126/scisignal.aat9773.
Sci Signal. 2018.
PMID: 30301790
Free PMC article.